Revenue
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings, Inc. (DNA)
Price$10.08Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M | $76.7M | $54.2M |
| Research & development | $243.8M | $424.1M | $580.6M | $1.05B | $1.15B | $159.8M | $96.3M |
| Operating expenses | $485.4M | $786.8M | $1.12B | $2.69B | $2.14B | $213.7M | $125.8M |
| Operating income | −$315.3M | −$559.8M | −$864.4M | −$2.21B | −$1.83B | −$137.0M | −$71.6M |
| Operating margin | −185.29% | −246.54% | −343.76% | −462.41% | −582.62% | −178.75% | −132.14% |
| EBITDA | −$256.3M | −$496.7M | −$793.9M | −$2.17B | −$1.80B | −$123.2M | −$60.8M |
| EBITDA margin | −150.62% | −218.79% | −315.72% | −453.50% | −573.35% | −160.67% | −112.29% |
| Net income | −$312.8M | −$547.0M | −$892.9M | −$2.10B | −$1.83B | −$126.6M | −$119.3M |
| Net profit margin | −183.81% | −240.94% | −355.08% | −440.63% | −583.12% | −165.16% | −220.23% |
| Basic EPSper basic share | -$5.64 | -$10.54 | -$18.37 | -$50.15 | -$86,400.00 | -$6,400.00 | -$6,400.00 |
| Diluted EPSper diluted share | -$5.64 | -$10.54 | -$18.37 | -$50.20 | -$88,960.00 | -$6,400.00 | -$6,400.00 |
Owners
Reported shareholders
8.19%of listed shares
BlackRock, Inc.4.28M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.19%4.28M shares |
VIKING GLOBAL INVESTORS LP | 6.84%3.58M shares |
Erste Asset Management GmbH | 4.85%2.54M shares |
BAILLIE GIFFORD & CO | 4.57%2.39M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.99%2.09M shares |
Anchorage Capital Group, L.L.C. | 3.34%1.75M shares |
Legal & General Group Plc | 3.19%1.67M shares |
STATE STREET CORP | 2.81%1.47M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.34%1.22M shares |
FORBES J M & CO LLP | 1.91%999.91K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.79%937.8K shares |
Allianz Asset Management GmbH | 1.50%785.8K shares |
UBS Group AG | 1.32%691.66K shares |
MILLENNIUM MANAGEMENT LLC | 1.22%638.68K shares |
AQR CAPITAL MANAGEMENT LLC | 1.19%621.63K shares |
SB INVESTMENT ADVISERS (UK) LTD | 1.17%610.73K shares |
GOLDMAN SACHS GROUP INC | 1.16%607.38K shares |
BANK OF AMERICA CORP /DE/ | 1.04%545.85K shares |
Prescott Group Capital Management, L.L.C. | 1.04%541.85K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.03%539.86K shares |
Percentages use 52.32M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 22, 2026Form 4 | Coen Steven P.See remarks | SellClass A Common Stock | 307 | $8.33 | $2.6K | 50.7K |
| Apr 17, 2026Form 4 | Coen Steven P.See remarks | SellClass A Common Stock | 324 | $7.95 | $2.6K | 50.3K |
| Apr 13, 2026Form 4 | Coen Steven P.See remarks | SellClass A Common Stock | 33.2K | $6.41 | $212.6K | 49.8K |
| Apr 10, 2026Form 4 | Canton BarryTenPercentOwner | SellClass A Common Stock · indirect | 124.7K | $6.43 | $802.0K | 436.4K |
| Apr 10, 2026Form 4 | Shetty Reshma P.See remarks | SellClass A Common Stock | 124.7K | $6.43 | $802.0K | 436.4K |
Community posts
Ginkgo links laboratory data services with Lilly’s TuneLab platform
Ginkgo ($DNA) Bioworks entered an agreement to provide experimental data-generation services to companies using Lilly’s ($LLY) TuneLab AI drug-discovery platform. Its Datapoints offering will supply small-molecule and antibody developabilit ...
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...
